Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIOGet Free Report) saw a large decrease in short interest in the month of February. As of February 29th, there was short interest totalling 8,700 shares, a decrease of 20.9% from the February 14th total of 11,000 shares. Based on an average trading volume of 5,300 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.7% of the shares of the company are sold short.

Xenetic Biosciences Stock Performance

XBIO stock opened at $4.17 on Thursday. The company has a market capitalization of $6.42 million, a price-to-earnings ratio of -1.40 and a beta of 2.61. Xenetic Biosciences has a fifty-two week low of $2.55 and a fifty-two week high of $5.97. The stock has a fifty day moving average of $3.76 and a 200-day moving average of $3.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xenetic Biosciences stock. Susquehanna International Group LLP boosted its stake in Xenetic Biosciences Inc (NASDAQ:XBIOFree Report) by 210.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,819 shares of the company’s stock after purchasing an additional 52,779 shares during the quarter. Susquehanna International Group LLP owned approximately 0.51% of Xenetic Biosciences worth $32,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.04% of the company’s stock.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Recommended Stories

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.